SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2017 / Cilt: 42 - Sayı: 1

Association of missense substitution of A49T and V89L in the SRD5A2 gene with prostate cancer in Turkish patients

Türk hastalarda SRD5A2 genindeki A49T ve V89L amino asit yer değişimlerinin prostat kanseri ile ilişkis

Alev KURAL
Ayten LİVAOGLU
Ilker TİNAY
Levent TURKERİ
Tulay CEVLİK
Sadi Konuk RESEARCH
Sebnem Tekin NEİJMANN
Pages
37–43
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Carrying the 49T allele was associated with higher likelihood of positive surgical margin status (27.5% in 49A vs

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine the association of missense substitution of alanine 49 threonine (A49T) and valine 89 leucine (V89L) in the steroid-5-alpha-reductase type II (SRD5A2) gene with prostate cancer in Turkish patients.Methods: Eighty patients with prostate cancer and 76 healthy control subjects were evaluated for A49T and V89L polymorphisms in the SRD5A2 gene mutations via real time fluorescence PCR and melting curve analysis.Results: Patients and controls were similar in terms of allele frequencies for polymorphic markers A49T and V89L in the SRD5A2 gene.
📊
Key Findings & Data:Most patients had T2b (51.3%), N0 (96.3%) stage tumors with Gleason Score of ≥ 6 (82.7%) and surgical margin in 28.8%.
💡
Conclusion & Impact:Carrying the 49T allele was associated with higher likelihood of positive surgical margin status (27.5% in 49A vs
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To determine the association of missense substitution of alanine 49 threonine (A49T) and valine 89 leucine (V89L) in the steroid-5-alpha-reductase type II (SRD5A2) gene with prostate cancer in Turkish patients.Methods: Eighty patients with prostate cancer and 76 healthy control subjects were evaluated for A49T and V89L polymorphisms in the SRD5A2 gene mutations via real time fluorescence PCR and melting curve analysis.Results: Patients and controls were similar in terms of allele frequencies for polymorphic markers A49T and V89L in the SRD5A2 gene. Most patients had T2b (51.3%), N0 (96.3%) stage tumors with Gleason Score of ≥ 6 (82.7%) and surgical margin in 28.8%. While 81.3% had no seminal vesicle invasion, 36.3% had capsular invasion. Carrying the 49T allele was associated with higher likelihood of positive surgical margin status (27.5% in 49A vs

Özet

Amaç: Türk hastalarda, steroid-5-alfa-redüktaz tip II; alfa polipeptit 2 3-oxo-5 alfa-steroid delta 4-dehidrogenaz alfa 2 (SRD5A2) genindeki Alanin 49 treonin (A49T) ve Valin 89 Lösin (V89L) amino asit yer değişimlerinin prostat kanseri ile ilişkisini tespit etmek.Metod: Prostat kanserli 80 hasta (ortalama(SD) yaş: 62,6 (7,8) yıl) ve 76 sağlıklı kontrol grubu olgusunda (ortalama(SD) yaş: 63,0 (8,7) yıl) SRD5A2 gen mutasyonalarından A49T ve V89L polimorfizmini eş zamanlı fluoresans PCR ve erime eğrisi analizi ile tespit ettik. Prognostik faktörler genel hasta popülasyonunda, A49T ve V89L polimorfizmleri açısından değerlendirildi.Bulgular: Hastalar ve kontrol olgularının polimorfik belirteçler için SRD5A2 genindeki A49T ve V89L polimorfizmleri de dahil allel sıklığı aynıydı. Hastaların çoğu T2b (% 51,3), N0 (% 96,3), Gleason skoru >= 6 (% 82,7) cerrahi sınırda (% 28,8) idi. Seminal vezikül invazyonu % 81,3'ünde yokken, % 36,3'ünde kapsül invazyonu vardı. 49T alleli taşıyanlarda cerrahi sınırın pozitif olabilirlik oranı (49A allelinde % 27,5, 49T allelinde %70, p = 0,038) ve Gleason skoru >= 7 (49A allelinde % 47,5, 49T allelinde % 100, p = 0,032) 49A alleli taşıyanlardan daha yüksekti. V89L polimorfizmi prognostik faktörlerle karşılaştırıldığında 89V veya 89L alleli taşıyanlar arasında fark görülmemiştir.Sonuç: Hasta ve kontrol grubunda SRD5A2 geninde polimorfik belirteçler allel sıklığı açısından anlamlı bir fark saptanmadı. T alleli sadece hasta grubunda gösterilmiştir. A49T polimorfizminde 49T alleli taşıyan hastalar yüksek tümör agresifliği ile ilişkili bulundu. 89V veya 89L alleli taşıyan hastalarda ise benzer prognostik karakteristikler kaydedildi

🔖

Cite This Article

KURAL, A., LİVAOGLU, A., TİNAY, I., TURKERİ, L., CEVLİK, T., RESEARCH, S. K., NEİJMANN, S. T. (2022). Association of missense substitution of A49T and V89L in the SRD5A2 gene with prostate cancer in Turkish patients. Türk Biyokimya Dergisi, Cilt: 42 - Sayı: 1, 37–43. https://ajindex.com/articles/621010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388–413
  2. Lindström S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Bälter KA, et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006;66:1729–43
  3. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3–12
  4. Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 2005;48:679–85
  5. Rittmaster RS. 5α-Reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008;22:389–402
  6. Singh AS, Chau CH, Price DK, Figg WD. Mechanisms of disease. Polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract Urol 2005;2:101–7
  7. Paz-y-Miño C, Witte T, Robles P, LIumipanta W, Diaz M, Arévalo M. Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Cancer Genet Cytogenet 2009;189:71–6
  8. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis- sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975–8
  9. Scariano JK, Treat E, Alba F, Nelson H, Ness SA, Smith AY. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate 2008;68:1798–805
  10. Wang C, Tao W, Chen Q, Hu H, Wen XY, Han R. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis. Prostate 2010;70:170–8
  11. Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, et al. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131:1571–3
  12. Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, et al. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 2007;67:1654–63
  13. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 [alpha]-reductase type II. Pharmacogenetics 2000;10:407–13
  14. Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, et al. The effects of 5alpha- redu